Agilon health/$AGL
1D1W1MYTD1Y5YMAX
Capital at risk
About Agilon health
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
- Ticker
- $AGL
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 856
- Headquarters
- Westerville, United States
- Website
- www.agilonhealth.com
Agilon health Metrics
BasicAdvanced
$1.5B
-
-$13.97
3.05
-
Price and volume
Market cap
$1.5B
Beta
3.05
52-week high
$133.04
52-week low
$7.48
Average daily volume
287K
Financial strength
Current ratio
1.081
Quick ratio
0.976
Long term debt to equity
0.081
Total debt to equity
0.147
Interest coverage (TTM)
-36.44%
Profitability
EBITDA (TTM)
-239.715
Gross margin (TTM)
0.23%
Net profit margin (TTM)
-3.92%
Operating margin (TTM)
-4.29%
Effective tax rate (TTM)
-0.26%
Revenue per employee (TTM)
$6,920,000
Management effectiveness
Return on assets (TTM)
-9.61%
Return on equity (TTM)
-78.94%
Valuation
Price to revenue (TTM)
0.252
Price to book
6.61
Price to tangible book (TTM)
8.99
Price to free cash flow (TTM)
-14.058
Free cash flow yield (TTM)
-7.11%
Free cash flow per share (TTM)
-6.378
Growth
Revenue change (TTM)
0.32%
Earnings per share change (TTM)
-26.87%
3-year revenue growth (CAGR)
22.91%
3-year earnings per share growth (CAGR)
37.84%
Bulls say / Bears say
Agilon Health delivered a strong financial turnaround in Q2 2026, growing total revenues by 7% to $1.495 billion, achieving a gross profit of $107 million and net income of $18 million, and posting Adjusted EBITDA of $70 million, compared to losses in Q2 2025 (SEC)
Management raised full-year 2026 guidance, boosting total revenue outlook to $5.775 billion–$5.860 billion (from $5.680 billion–$5.805 billion), medical margin to $465 million–$505 million, and Adjusted EBITDA to $75 million–$95 million, reflecting confidence in execution and favorable cost trends (SEC)
Agilon Health maintains a solid liquidity position with $257 million of cash, cash equivalents, and marketable securities against only $32 million of debt, plus an additional $83 million held in unconsolidated ACO model entities, providing financial flexibility for growth initiatives (SEC)
Platform membership contracted 10% year-over-year to 549,000 members (including a 12% drop in Medicare Advantage membership to 437,000), highlighting challenges in member growth amid disciplined contracting and market exits (SEC)
Medical margin’s turnaround to $197 million in Q2 2026 was driven in part by favorable prior-year claims development, a one-time benefit that may not recur if claims experience normalizes (SEC)
Revenue growth relies heavily on favorable payor contracting and pricing improvements, exposing Agilon to renegotiation and reimbursement risks if Medicare Advantage payor terms deteriorate (SEC)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
Agilon health News
AllArticlesVideos
agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference
Business Wire3 weeks ago
Agilon Health Q2 Earnings Call Highlights
MarketBeat1 month ago
Kaskela Law Firm Announces Investigation of Agilon Health, Inc. (AGL) and Encourages Long-Term AGL Shareholders with Investment Losses to Contact the Firm
Business Wire2 months ago
Funds containing Agilon health
AllEURUSDGBP
Fund name | Fund size | $AGL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.